oral MET kinase inhibitor

approved for clinical use in NSCLC

internal HTS and SBDD

Clinical Cancer Research

Merck KGaA

9.      The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks